Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
These regulatory approvals signify a significant milestone for Venus Remedies Limited
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Subscribe To Our Newsletter & Stay Updated
